Alumis And ACELYRIN's Merger Marks A New Era For Late-Stage Biopharma Advancements

RTTNewsFeb 7 10:57 ET

Alumis and Acelyrin Sign Merger Agreement

Yahoo FinanceFeb 7 10:44 ET

Wells Fargo Maintains Acelyrin(SLRN.US) With Buy Rating

Moomoo NewsFeb 7 07:33 ET · Ratings

Piper Sandler Sticks to Their Buy Rating for ACELYRIN, INC. (SLRN)

TipRanksFeb 7 06:50 ET · Ratings

ACELYRIN, INC. (SLRN) Receives a Buy From Wells Fargo

TipRanksFeb 7 06:38 ET · Ratings

Shareholder Alert: Ademi & Fruchter LLP Investigates Whether ACELYRIN, INC. Is Obtaining a Fair Price for Its Public Shareholders

BusinesswireFeb 6 16:57 ET

Alumis and ACELYRIN To Merge; ACELYRIN Stockholders To Get 0.4274 Alumis Shares Each; Post-Transaction Ownership Of Combined Compsny Alumis 55%, ACELYRIN 45%.

BenzingaFeb 6 16:31 ET

Express News | Alumis Inc: Alumis & ACELYRIN's Combined Pro Forma Cash Position of About $737 Mln as of Dec 31, 2024, Provides Runway Into 2027

ReutersFeb 6 16:20 ET

ACELYRIN: Evaluation Underway of Development Plan for Lonigutamab to Confirm Differentiation in a Cap Efficient Manner >SLRN

Dow JonesFeb 6 16:20 ET

Alumis and ACELYRIN to Merge in an All-Stock Transaction >ALMS SLRN

Dow JonesFeb 6 16:20 ET

Express News | Alumis Inc: Combined Company Will Operate Under Alumis Name With Current Alumis Executive Team

ReutersFeb 6 16:19 ET

Express News | Alumis Inc: Alumis & ACELYRIN Stockholders to Own About 55% & About 45%, Respectively, of Combined Co on Fully Diluted Basis

ReutersFeb 6 16:18 ET

Acelyrin Inc Trading Halted, News Pending

TipRanksFeb 6 16:16 ET

Press Release: Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

Dow JonesFeb 6 16:15 ET

Express News | Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-Mediated Diseases

ReutersFeb 6 16:15 ET

Express News | Trading Halt: Halted at 4:13:29 P.m. ET - Trading Halt: Halt News Pending

BenzingaFeb 6 16:13 ET

ACELYRIN, INC. Ends Key Agreement With Affibody

TipRanksJan 31 16:49 ET

Express News | ACELYRIN Inc - Terminates License Agreement With Affibody

ReutersJan 31 16:26 ET

Morgan Stanley Maintains Acelyrin(SLRN.US) With Hold Rating, Maintains Target Price $5

Moomoo NewsJan 8 09:31 ET · Ratings

A Quick Look at Today's Ratings for Acelyrin(SLRN.US), With a Forecast Between $5 to $20

Moomoo NewsJan 8 08:00 ET · Ratings